| A/G ratio | >1 |
| Albumin | | Men-Women | 3.8–5.0 g/dl | 38–50 g/L
| | Pregnancy | 1.9–4.0 g/dl | 19–40 g/L | |
| Alkaline phosphatase | | Men | 20–70 U/L | | Women | 20–150 U/L | | Pregnancy | 60–200 U/L | |
| Amylase | | Men | 50–150 U/L | | Women | 60–180 U/L | | Pregnancy | 90–350 U/L | |
| AST | | Men | 8–20 U/L | | Women | 6–18 U/L | | Children | 25–75 U/L | |
| Bilirubin (total) | 0.2–1.0 mg/dl |
| Bilirubin (indirect or unconjugated) | 0.2–0.8 mg/dl |
| Bilirubin (direct or conjugated) | 0–0.2 mg/dl |
| Bleeding time | | Earlobe (Duke) | <8 minutes | | Forearm (Ivy) | <9.5 minutes | |
BUN (UREA)
| | Adults | 8–23 mg/dL | 1.7–8.0 mmol/L
| | Children | 5–15 mg/dL | 1.5–5.0 mmol/L | | Pregnancy | 5–12 mg/dL | 1.5–4.5 mmol/L | |
| Calcium | | Men | 8.8–10.0 mg/dl | 2.15–2.55 mmol/L | | Women | 9.0–10.5 mg/dl | 2.15–2.55 mmol/L | | Pregnancy | 8.1–9.5 mg/dl | 2.02–-2.40 mmol/L | | Children | 9.2–11.0 mg/dl | 2.30–2.75 mmol/L | |
| Chloride | | Men | 98–106 mmol/L | | Women | 98–106 mmol/L | | Pregnancy | 93–100 mmol/L | |
| Cholesterol: total | | Desirable | 140–200 mg/dl | 3.6–5.17 mmol/L | | Borderline | 201–-239 mg/dl | 5.2–6.18 mmol/L | | High | >240 mg/dl | >6.18 mmol/L | |
| Cholesterol: HDL | | Men | 35–70 mg/dl | 0.9–1.8 mmol/L | | Women | 35–85 mg/dl | 0.9–2.2 mmol/L | | Children | 30–65 mg/dl | 0.8–1.7 mmol/L | |
| Cholesterol: LDL | | Desirable | <130 mg/dl | <3.4 nmol/L
| | Borderline | 130–159 mg/dl | 3.4–4.1 nmol/L | | High | ≥160 mg/dl | >4.1 nmol/L | |
| Cholesterol: VLDL | 25–50% of Total Cholesterol |
CO2 content bicarbonate
| | Men | 23–30 mmol/L | | Women | 21–30 mmol/L | | Pregnancy | 18–25 mmol/L | |
| CPK (CK) | | Men | 5–100 IU/L | | Women | 10–70 IU/L | | Pregnancy | 5–40 IU/L | |
| Creatinine | | Men | 0.6–1.2 mg/dl | 53–106 µmol/L
| | Women | <1.5 mg/dl | <133 µmol/L | | Pregnancy | <1.0 mg/dl | <88 µmol/L | | Children | 0.3–0.7 mg/dl | 26–62 µmol/L | |
| Creatinine clearance | | Men | 70–130 ml/min | | Women | 91–130 ml/min | | Pregnancy | 120–160 ml/min | |
| DHEAS | | Men | 80–640 µg/dl | 217–1740 µmol/L | | Women | <350 µg/dl | <950 µmol/L | | Women: Moderate Increase | 350–700 µg/dl | 950–1900 µmol/L | | Women: High Levels | >700 µg/dl | >1900 µmol/L | |
| Estradiol | | Men | 13–42 pg/ml | 48–154 pmol/L
| | Women
(Proliferative Phase) | 60–250 pg/ml | 220–918 pmol/L | Women
(Luteal Phase) | 75–450 pg/ml | 275–1650 pmol/L | Women
(Menopausal) | <10 pg/ml | <40 pmol/L | Women
(Menopausal on estrogen replacement) | 50–100 pg/ml | 184–367 pmol/L | |
| FSH | | Men | 4–25 mIU/ml | 4–25 IU/L
| | Women | 4–30 mIU/ml | 4–30 IU/L | | Women (Midcycle) | 2 x baseline | | | Women (Menopausal) | 40–250 mIU/ml | 40–250 IU/L | |
| FTI | | Men | 1.3–4.2 | | Women | 1.75–4.95 | |
| Glucose: fasting | | Men | 70–110 mg/dl | 3.9–6.1 mmol/L
| | Women | 75–115 mg/dl | 4.2–6.4 mmol/L | | Pregnancy | 60–105 mg/dl | 3.3–5.8 mmol/L | |
| Glucose: 2 hour postprandial | |
| Glucose: pregnancy screening | | Post 50 G Glucose Load | <135 mg/dl | <7.5 mmol/L | |
| Glucose: gestational diabetes criteria | Post 100 G Glucose Load | Fasting | 95 mg/dl | 5.3 mmol/L | | 1-Hour | 180 mg/dl | 10.0 mmol/L | | 2-Hour | 155 mg/dl | 8.6 mmol/L | | 3-Hour | 140 mg/dl | 7.8 mmol/L | If two or more of these values are exceeded, gestational diabetes is present. |
| Hepatitis B surface antigen | Negative |
| LDH | | Men | 95–200 U/L | | Women | 200–450 U/L | | Pregnancy | 200–450 U/L | |
| LH | | Men | 7–24 mIU/ml | 7–24 IU/L | | Women
(Follicular Phase) | 6–30 mIU/ml | 6–-30 IU/L | Women
(Midcycle) | >3x baseline | | Women
(Menopausal) | >30 mIU/ml | >30 IU/L | |
| Magnesium | | Men | 1.7–2.8 mg/dl | 0.70–1.15 mmol/L
| | Women | 2–3 mg/dl | 0.82–1.24 mmol/L | | Pregnancy | 1.6–2.1 mg/dl | 0.66–0.86 mmol/L | | Therapeutic Range in Pre-eclampsia | 4–7 mEq/L | 1.65–2.88 mmol/L | |
Phosphorus phosphate
| | Men | 2.7–4.5 mg/dl | 0.87–1.45 mmol/L | | Women | 3.0–4.5 mg/dl | 0.97–-1.45 mmol/L | |
| Platelets | 150,000–350,000/cu. mm
| 150–450 x 109/L |
|
| Potassium | | Men | 3.5–5.0 mEq/L | 3.5–5.0 mmol/L | | Women | 3.5–5.0 mEq/L | 3.5–5.0 mmol/L | | Pregnancy | 3.3–4.1 mEq/L | 3.3–4.1 mmol/L | |
| Pregnancy test | Negative |
| Prolactin | | Men | <20 ng/ml | 53–360 mIU/L
| | Women | 2–ng/ml | 53–360 mIU/L | | Pregnancy | 50–400 ng/ml | 53–360 mIU/L | |
| Protein (total) | | Men-Women | 3.8–.0 g/dl | 38–50 g/L | | Pregnancy | 3.0–4.0 g/dl | 30–40 g/L | |
| PT | | Men-Women | 10–14 seconds (100%) | | Therapeutic Range on oral anticoagulants | 2–2.5 times normal, but not >30 seconds | |
| PTT | | PTT | 30–seconds | | APTT | 16–25 seconds | Therapeutic
Range on oral anticoagulants | 2–2.5 times normal | |
SGGT γGT
| | Men | 8–20 U/L | | Women | 4–18 U/L | |
SGOT AST
| | Men | 8–20 IU/L | | Women | 6–18 IU/L | | Children | 25–75 IU/L | |
SGPT ALT
| | Men | 7–17 U/L | | Women | 0–35 U/L | | Pregnancy | 0–35 U/L | |
| Sodium | | Men | 135–145 mEq/L | 135–145 mmol/L
| | Women | 136–145 mEq/L | 135–145 mmol/L | | Pregnancy | 130–140 mEq/L | 130–140 mmol/L | |
T3 (total)
| | Men | 120–195 ng/dl | 1.2–2.6 nmol/L | | Women | 70–190 ng/dl | 1.0–2.6 nmol/L | | Pregnancy | 100–220 ng/dl | 1.1–2.6 nmol/L | |
| T4 (total) | | Men | 5–12.5 µg/dl | 64.4–161 nmol/L | | Women | 5–12 µg/dl | 64.4–154 nmol/L | | Pregnancy | 10–17 µg/dl | 128.7–2.9 nmol/L | |
| T7 (FTI) | | Men | 1.3–4.2 | | Women | 1.75–4.95 | |
| TSH | | Men | 0.5–6 mIU/L | | Women | 4–5 mIU/L | |
| Triglycerides | | Men | 40–160 mg/dl | 0.45–1.81 mmol/L | | Women | 35–135 mg/dl | 0.40–1.53 mmol/L | | Pregnancy | <260 mg/dl | <2.94 mmol/L | | Children | 30–138 mg/dl | 0.34–1.56 mmol/L | |
| Uric acid | | Men | 3.5–7.2 mg/dl | 0.21–0.43 mmol/L | | Women | 1.5–6.0 mg/dl | 0.09–0.36 mmol/L | | Pregnancy | 1.2–4.5 mg/dl | 0.07–0.27 mmol/L | |
